Search the Newsreel

Replimune (REPL) Slumps As Losses Mount And Legal Scrutiny Grows

Replimune Group Inc. (REPL) stock plunged by 18.66% amidst negative sentiment following its latest clinical trial outlook, wider-than-expected fiscal 2026 net losses, and a newly launched legal investigation into potential fiduciary duty breaches. Wedbush raised its price target from $6 to $9 but maintained …

Repligen Corp Bottom Line Declines In Q2

(RTTNews) - Repligen Corp (RGEN) announced a profit for second quarter that Drops, from last year The company's bottom line totaled $5.01 million, or $0.09 per share. This compares with $14.87 million, or $0.26 per share, last year. Excluding items, Repligen Corp reported adjusted …

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026 Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 11.9% year on year to $204.1 million. The company expects the full year's revenue to be around …

Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance

Repligen Corporation announced strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase and 13% organic growth. Due to this performance and continued order momentum, the company has raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and …

Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance

Repligen reported strong second-quarter 2026 results with revenue of $204.1 million, a 12% year-over-year increase, and adjusted diluted EPS of $0.54. The company has raised its full-year 2026 guidance for organic revenue growth and adjusted diluted EPS, driven by continued order momentum and portfolio …

First Trust Advisors LP Has $43.57 Million Stock Holdings in ePlus inc. $PLUS

First Trust Advisors LP significantly increased its stake in ePlus inc. (NASDAQ:PLUS) by 118.2% in the first quarter, now holding 579,047 shares valued at $43.57 million. Other institutional investors have also adjusted their positions in the software maker. The article also details ePlus's stock …

ePlus inc (PLUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of ePlus inc (PLUS), highlighting its current price momentum score as 3.61 and placing it within the Software & IT Services industry. The analysis identifies key support at $81.36 and resistance at $94.59, suggesting a range-bound swing trading …

Repligen (NASDAQ:RGEN) Shares Gap Up Following Better-Than-Expected Earnings

Repligen to Acquire BioLife Solutions, Enhancing Cell Therapy Capabilities

Repligen Corporation announced its intent to acquire BioLife Solutions for approximately $1.5 billion, a strategic move aimed at strengthening Repligen's position in the rapidly expanding cell therapy market. The acquisition, valued at $31.00 per share, combines 64% Repligen stock and 36% cash, with the …

EPL Limited Revenue Breakdown – NSE:EPL

ePlus inc (PLUS) Income Statement

This article provides a detailed quarterly and annual income statement for ePlus inc (PLUS), offering insights into its financial performance, including revenue, operating expenses, and net income. It also includes an FAQ section explaining how to read the income statement and defining key financial …

Replimune Group Inc (REPL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Replimune Group Inc (REPL), detailing its volatility, financial risk, and investment risk metrics. It includes data such as Beta vs S&P 500 index, VaR, maximum drawdown, daily returns (best and worst), Sharpe Ratio, and various volatility measures …

Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy

Shares of Replimune fell significantly after FDA reviewers raised concerns about the efficacy of its lead cancer therapy, RP1, for advanced melanoma. The FDA's briefing documents questioned the methodology of Replimune's IGNYTE study, suggesting that the tumor response and duration may have been overstated, …

PLUS | ePlus Inc Executive Compensation

This page provides an overview of ePlus Inc (PLUS) executive compensation, noting that specific details are based on recent SEC DEF 14A filings. It also mentions the estimated median employee salary at ePlus and lists various financial and government contract data points related to …

EPL Limited Issues and Allots Commercial Papers Worth ₹60 Crore at 7.37% Discount Rate

Repligen Corp (RGEN) Cash Flow

This article provides a detailed cash flow statement for Repligen Corp (RGEN), including quarterly and annual data for operating, investing, and financing activities. It also defines these cash flow types and provides key figures for RGEN, such as operating cash flow, capital expenditures, and …

Replimune Group Market Sentiment

This article provides an overview of the market sentiment for Replimune Group (REPL), highlighting analyst consensus, short interest, options flow, and recent insider activity. Key signals indicate a "Market Perform" consensus from analysts, a significant 49.9% short float that is trending downwards, and a …

Repligen (RGEN) Q2 Earnings: What To Expect

Repligen (RGEN) is set to report its Q2 earnings this Tuesday morning. Analysts expect the biopharma manufacturing company's revenue to grow 10.7% year over year, a slowdown from the previous year. The company beat revenue and EPS expectations last quarter, and analysts have generally …

REPL|Replimune Group Inc|Price:14.960|Chg%:-0.230

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

REPL|Replimune Group Inc|Price:12.060|Chg%:-0.800

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

Seplat Energy PLC Revenue Breakdown – LSE:SEPL

Key deals this week: Stripe, IBM, Repligen, LXP Industrial Trust and more

[Business mergers and acquisitions concept. Share acquisition, asset business acquisition, amalgamation. Business review and development model. The abbreviation M and A on smart background, copy space.] Parradee Kietsirikul Here's a list of key deals reported across sectors this week: * Payments firm Stripe (STRIP …

Replimune Group (REPL) Q2 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline Advances - Trough Earnings Signal

Repligen Corporation Revenue Breakdown – NASDAQ:RGEN

This article details Repligen Corporation's revenue breakdown. Last year, the company generated $738.26 million USD, with its Filtration segment being the top performer at $402.79 million USD. North America was the largest regional contributor, accounting for $361.75 million USD.

ePlus inc. Revenue Breakdown – NASDAQ:PLUS

ePlus inc. (NASDAQ: PLUS) reported total revenue of $2.44 billion USD last year. The largest portion of this revenue, $1.98 billion USD, came from its "Third-party Hardware, Third-party Perpetual and Subscription Software, and Third-party Maintenance, Software Assurance, and Other Third-party Services" segment. The United …

Did ePlus’ (PLUS) Expanded Share Authorization Quietly Redefine Its Capital Flexibility Playbook?

ePlus Inc. (PLUS) received board approval to increase its authorized common shares from 50 million to 75 million at its 2026 Annual Meeting of Shareholders, subject to shareholder approval. This move aims to provide the company with greater financial flexibility for future initiatives like …

REPL|Replimune Group Inc|Price:9.700|Chg%:-0.760

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

ePlus inc (PLUS) Financial Health: Profitability & Balance Sheet Analysis

ePlus inc (PLUS) has a robust financial status with a current financial score of 8.72, ranking 59th out of 485 in the Software & IT Services industry. The company reported a quarterly revenue of $581.63M, marking a 16.77% year-over-year increase, and a net profit …

Repligen Corp|Price:131.970|Chg%:-5.630

This article provides a company profile for Repligen Corporation (RGEN), a global life sciences company specializing in bioprocessing technologies. It details the company's focus areas, product portfolio, and key financial information. The article also lists company executives, their shareholdings, and institutional ownership data for …

Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Repligen Corp (RGEN) by business segment and by region. For FY2025, filtration products were the largest segment, contributing 54.58% of revenue, while North America was the largest regional market at 49.00%. The data highlights the company's …

ePlus announces annual shareholder meeting

ePlus has announced its 2026 annual shareholder meeting will be held on September 10, 2026, in Herndon, Virginia. Key agenda items include the election of nine directors, an advisory vote on executive compensation, and the ratification of Deloitte as the independent auditor. Shareholders will …

EPLUS INC SEC Filing (Jul 24, 2026)

This article reports on an SEC filing (Form type ARS) by EPLUS INC (PLUS) on July 24, 2026. The filing has a low impact and neutral sentiment according to Rhea-AI. The article also provides recent news and other SEC filings for EPLUS INC, along …

ePlus inc. (PLUS) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of ePlus inc. (PLUS) stock, including its current price, historical performance, key financial metrics, and company overview. It details the company's IT solutions across three segments: Product Services, Professional Services, and Managed Services, and presents analyst …

Replimune Group Inc (REPL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Replimune Group Inc (REPL), highlighting its major institutional holders and their proportion of shares. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent activities of top shareholders. Additionally, it lists several …

3 Reasons to Sell PLUS and 1 Stock to Buy Instead

3 Reasons to Sell PLUS and 1 Stock to Buy Instead ePlus has been treading water for the past six months, holding steady at $86.95. The stock also fell short of the S&P 500's 7.9% gain during that period. Is now the time to …

PLUS|ePlus inc|Price:86.930|Chg%:-0.680

ePlus inc. (PLUS) is a technology solutions and services company offering AI, security, cloud, and networking solutions, along with various managed and professional services. The article provides an overview of the company's profile, including its market cap, P/E ratio, key executives, and institutional shareholdings. …